About GW Pharmaceuticals (LON:GWP)
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-51.18%
Return on Assets-44.49%
GW Pharmaceuticals (LON:GWP) Frequently Asked Questions
What is GW Pharmaceuticals' stock symbol?
GW Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "GWP."
Who are GW Pharmaceuticals' key executives?
GW Pharmaceuticals' management team includes the folowing people:
- Geoffrey W. Guy, Executive Chairman of the Board
- Justin Gover, Chief Executive Officer, Director
- Adam David George, Chief Financial Officer, Company Secretary, Director
- Christopher John Tovey, Chief Operating Officer, Executive Director
- Julian S. Gangolli, Executive Director
- James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
- Cabot Brown, Non-Executive Independent Director
- Thomas Gerard Lynch, Non-Executive Independent Director
- Catherine J. Mackey Ph.D., Non-Executive Independent Director
- Alicia Secor, Non-Executive Independent Director
Has GW Pharmaceuticals been receiving favorable news coverage?
Headlines about GWP stock have been trending somewhat positive on Monday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. GW Pharmaceuticals earned a news impact score of 0.01 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 44.86 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of GW Pharmaceuticals?
Shares of GWP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is GW Pharmaceuticals' stock price today?
One share of GWP stock can currently be purchased for approximately GBX 716.60.
How can I contact GW Pharmaceuticals?
GW Pharmaceuticals' mailing address is Sovereign House, Vision Park, CAMBRIDGE, 00000, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1223-266800.
MarketBeat Community Rating for GW Pharmaceuticals (GWP)MarketBeat's community ratings are surveys of what our community members think about GW Pharmaceuticals and other stocks. Vote "Outperform" if you believe GWP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GWP will underperform the S&P 500 over the long term. You may vote once every thirty days.